Samantha Jaglowski, MD, MPH, on Next Steps Regarding Tisagenlecleucel for Patients with DLBCL

The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.

Samantha Jaglowski, MD, MPH, associate professor at The Ohio State University Comprehensive Cancer Center, discussed next steps regarding her analysis of the CAR T-cell therapy tisagenlecleucel (Kymriah) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) using the Center for International Blood and Marrow Transplant Research (CIBMTR) database at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, in Orlando, Florida.

Really the next step is, this is really very germinal, this is the first readout of the tisagen data submitted to the CIBMTR, so the next steps are really going to be to accrue more patients. There’s a goal of collecting 2,500 tisagen patients and currently there are a bit over 100 that we’re reporting on, so the goal is for this to be a really large suppository of data and we’re not there yet. We will be there, but you know it’ll be important to continue to follow this with time.

Related Videos
Olivier Danos, PhD, on Refining and Specifying AAV Gene Therapy
Paul Harmatz, MD, on Reducing GAGs in MPS Type 2 With RGX-121 Gene Therapy
Francesca Barone, MD, PhD, on Positive Biomarker, Overall Survival Data With CAN-3110 in High-Grade Glioma
Sung-Yun Pai, MD, on High T-Cell Reconstitution in X-SCID With Lentiviral Gene Therapy
Related Content
© 2023 MJH Life Sciences

All rights reserved.